Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinical practice guidelines on iron therapy: A critical evaluation.

Del Vecchio L, Locatelli F.

Hemodial Int. 2017 Jun;21 Suppl 1:S125-S131. doi: 10.1111/hdi.12562. Epub 2017 Apr 24. Review.

PMID:
28436206
2.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
3.

Therapy of anemia: is it only a number to reach or are there other variables to control?

Del Vecchio L, Locatelli F.

Blood Purif. 2013;36(1):37-40. doi: 10.1159/000350584. Epub 2013 May 25. Review.

PMID:
23735594
4.

Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.

Del Vecchio L, Locatelli F.

Expert Rev Hematol. 2014 Aug;7(4):495-506. doi: 10.1586/17474086.2014.941349. Review.

PMID:
25025373
5.

Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.

Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1814-21. doi: 10.2215/CJN.02600315. Epub 2015 Aug 18.

6.

Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.

Kapoian T.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S21-8. doi: 10.1053/j.ajkd.2008.09.004.

PMID:
19010258
7.

An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.

Del Vecchio L, Locatelli F.

Expert Opin Drug Saf. 2016 Aug;15(8):1021-30. doi: 10.1080/14740338.2016.1182494. Epub 2016 May 13. Review.

PMID:
27149639
8.

Anemia management in cancer patients with chronic kidney disease.

Deak AT, Troppan K, Rosenkranz AR.

Eur J Intern Med. 2016 Dec;36:13-19. doi: 10.1016/j.ejim.2016.08.036. Epub 2016 Sep 15. Review.

PMID:
27640913
9.

Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

De Nicola L, Locatelli F, Conte G, Minutolo R.

Drugs. 2014 Feb;74(2):159-68. doi: 10.1007/s40265-013-0175-3.

PMID:
24442793
10.
11.

Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients.

Evans M, Carrero JJ, Bellocco R, Barany P, Qureshi AR, Seeberger A, Jacobson SH, Hylander-Rössner B, Rotnitzky A, Sjölander A.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1892-1901. doi: 10.1093/ndt/gfw328.

PMID:
27672090
12.

Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.

Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, Harwood L, Sood MM, Soroka SD, Bass A, Manns BJ.

Am J Kidney Dis. 2013 Nov;62(5):860-73. doi: 10.1053/j.ajkd.2013.08.001. Epub 2013 Sep 17.

PMID:
24054466
13.

Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.

Locatelli F, Mazzaferro S, Yee J.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1269-80. doi: 10.2215/CJN.00080116. Epub 2016 May 16. Review.

14.

The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.

Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2014 Apr;29(4):843-50. doi: 10.1093/ndt/gft424. Epub 2013 Oct 29.

15.

Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?

Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y.

Clin Exp Nephrol. 2012 Dec;16(6):819-26. doi: 10.1007/s10157-012-0694-3. Epub 2012 Sep 29. Review.

16.

Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.

Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, Mangione F, Esposito P, Dal Canton A; REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group.

Nephrol Dial Transplant. 2013 Dec;28(12):3035-45. doi: 10.1093/ndt/gft338. Epub 2013 Oct 21.

PMID:
24145459
17.

Economic considerations in a changing anemia environment.

Pizzi LT.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S29-33. doi: 10.1053/j.ajkd.2008.09.001.

PMID:
19010259
18.

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Wyck DV, Meier Y, Larroque S, Perrin A, Roger SD.

Clin Nephrol. 2017 Dec;88(12):301-310. doi: 10.5414/CN109198.

19.

Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.

Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A.

Am J Kidney Dis. 2016 Nov;68(5):677-690. doi: 10.1053/j.ajkd.2016.04.018. Epub 2016 Jun 16. Review.

PMID:
27321965
20.

Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience.

Gardiner R, Roshan D, Brennan A, Connolly D, Murray S, Reddan D.

Ir J Med Sci. 2019 Feb;188(1):223-230. doi: 10.1007/s11845-018-1823-0. Epub 2018 Apr 27.

PMID:
29704093

Supplemental Content

Support Center